Ascendis Pharma/$ASND
1D1W1MYTD1Y5YMAX
Capital at risk
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
- Ticker
- $ASND
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,189
- Headquarters
- Hellerup, Denmark
- Website
- ascendispharma.com
Ascendis Pharma Metrics
BasicAdvanced
$17B
19.21
$13.60
-
-
Price and volume
Market cap
$17B
52-week high
$282.15
52-week low
$203.80
Average daily volume
544K
Financial strength
Current ratio
2.991
Quick ratio
2.229
Long term debt to equity
26.776
Total debt to equity
31.331
Interest coverage (TTM)
2.01%
Profitability
EBITDA (TTM)
305.831
Gross margin (TTM)
91.30%
Net profit margin (TTM)
70.84%
Operating margin (TTM)
24.70%
Effective tax rate (TTM)
-658.14%
Revenue per employee (TTM)
$1,021,540
Management effectiveness
Return on assets (TTM)
9.58%
Return on equity (TTM)
118.78%
Valuation
Price to earnings (TTM)
19.208
Price to revenue (TTM)
13.324
Price to book
11.94
Price to tangible book (TTM)
11.97
Price to free cash flow (TTM)
41.629
Free cash flow yield (TTM)
2.40%
Free cash flow per share (TTM)
6.275
Growth
Revenue change (TTM)
113.35%
Earnings per share change (TTM)
-356.73%
3-year revenue growth (CAGR)
106.35%
10-year revenue growth (CAGR)
66.26%
3-year earnings per share growth (CAGR)
2.54%
10-year earnings per share growth (CAGR)
18.61%
Bulls say / Bears say
The board authorized a $120 million share repurchase program for 2026, underlining management’s confidence in the firm’s cash flow and commitment to returning capital to shareholders. (Reuters)
The FDA approved YUVIWEL (navepegritide) under the Accelerated Approval Program on February 27, 2026, as the first once-weekly treatment to increase linear growth in children with achondroplasia. (Reuters)
The U.S. FDA granted orphan drug exclusivity to YUVIWEL, providing seven years of market protection for the treatment of pediatric achondroplasia. (Reuters)
The FDA noted that continued approval for YUVIWEL may depend on confirmation of clinical benefit in post-approval trials, exposing the therapy to potential regulatory setbacks. (Reuters)
BridgeBio Pharma reported positive Phase 3 results for oral infigratinib in achondroplasia, highlighting a competitive threat to Ascendis’ YUVIWEL in 2026. (Reuters)
Management expects European approval for YUVIWEL only in Q4 2026, potentially delaying expansion into key EU markets. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
Upcoming events
No upcoming events
Ascendis Pharma News
AllArticlesVideos
Funds containing Ascendis Pharma
AllUSDGBP
Fund name | Fund size | $ASND weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.10% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.